Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Breaking & Recent News Black Diamond Therapeutics Inc BDTX

Healthcare Biotechnology
Black Diamond Therapeutics, Inc. is a clinical-stage oncology company focused on the development of MasterKey therapies that address families of oncogenic mutations in clinically validated targets. The Company’s MasterKey therapies are designed to address broad genetically defined patient populations, overcome resistance, minimize wild-type mediated toxicities, and be brain penetrant to treat... see more

Recent & Breaking News (NDAQ:BDTX)

Black Diamond Therapeutics Announces Spinout of Launchpad Therapeutics, Inc., an Antibody-Focused Precision Oncology Company

GlobeNewswire December 12, 2022

Black Diamond Therapeutics to Participate in Upcoming Investor Conferences

GlobeNewswire November 9, 2022

Black Diamond Therapeutics Reports Third Quarter 2022 Financial Results and Provides Corporate Update

GlobeNewswire November 8, 2022

Black Diamond Therapeutics Presents Preclinical Data on BDTX-1535 and BDTX-4933 at the 34th EORTC-NCI-AACR Symposium on Molecular Targets and Cancer Therapeutics

GlobeNewswire October 26, 2022

Black Diamond Therapeutics to Participate in Upcoming Investor Conferences

GlobeNewswire September 6, 2022

Black Diamond Therapeutics Reports Second Quarter 2022 Financial Results and Provides Corporate Update

GlobeNewswire August 9, 2022

Black Diamond Therapeutics to Present at the 2022 Wedbush PacGrow Healthcare Virtual Conference

GlobeNewswire August 3, 2022

Black Diamond Therapeutics to Present at the Jefferies Global Healthcare Conference

GlobeNewswire June 6, 2022

Black Diamond Therapeutics Appoints Sergey Yurasov, M.D., Ph.D., as Chief Medical Officer

GlobeNewswire June 1, 2022

Black Diamond Therapeutics to Present at the H.C. Wainwright Global Investment Conference

GlobeNewswire May 17, 2022

Black Diamond Therapeutics Announces Publication of New Computational and Functional Analyses of HER2 Mutations Based on its Proprietary MAP Discovery Engine

GlobeNewswire May 12, 2022

Black Diamond Therapeutics Reports First Quarter 2022 Financial Results and Provides Corporate Update

GlobeNewswire May 11, 2022

Black Diamond Therapeutics Announces Pipeline Prioritization and Workforce Realignment

GlobeNewswire April 25, 2022

Black Diamond Therapeutics Announces First Patient Dosed in Phase 1 Study of BDTX-1535, a MasterKey Inhibitor of EGFR for the Treatment of Glioblastoma and Non-Small Cell Lung Cancer

GlobeNewswire April 18, 2022

Black Diamond Therapeutics to Present at the Canaccord Genuity Horizons in Oncology Virtual Conference

GlobeNewswire April 7, 2022

Black Diamond Therapeutics Appoints Wendy L. Dixon to its Board of Directors

GlobeNewswire April 7, 2022

Black Diamond Therapeutics Reports Fourth Quarter and Full Year 2021 Financial Results and Provides Corporate Update

GlobeNewswire March 17, 2022

Black Diamond Therapeutics to Participate at the Cowen 42nd Annual Health Care Conference

GlobeNewswire March 2, 2022

Black Diamond Therapeutics Appoints Elizabeth Montgomery as Chief People Officer

GlobeNewswire February 22, 2022

Black Diamond Therapeutics Announces FDA Allowance of IND Application for BDTX-1535, A MasterKey Inhibitor of EGFR for the Treatment of Gliobastoma and Non-Small Cell Lung Cancer

GlobeNewswire January 11, 2022